BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26334961)

  • 1. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
    Garg T; Goyal AK; Rath G; Murthy RS
    Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
    Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
    Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
    Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
    Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic Evaluation of Guar Gum Coated Chitosan Nanoparticle Against Experimental Tuberculosis.
    Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
    J Biomed Nanotechnol; 2016 Mar; 12(3):450-63. PubMed ID: 27280243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs.
    Kaur R; Garg T; Das Gupta U; Gupta P; Rath G; Goyal AK
    Artif Cells Nanomed Biotechnol; 2016; 44(1):182-7. PubMed ID: 24992699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
    Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
    Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alginate microspheres of isoniazid for oral sustained drug delivery.
    Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK
    Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
    Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
    Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis.
    Garg T; Rath G; Goyal AK
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):997-1001. PubMed ID: 25682840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design.
    Chawla R; Jaiswal S; Mishra B
    Expert Opin Drug Deliv; 2014 Jan; 11(1):31-43. PubMed ID: 23802585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
    Pandey R; Zahoor A; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
    Xu W; Wei X; Wei K; Cao X; Zhong S
    Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis.
    Manca ML; Cassano R; Valenti D; Trombino S; Ferrarelli T; Picci N; Fadda AM; Manconi M
    J Pharm Pharmacol; 2013 Sep; 65(9):1302-11. PubMed ID: 23927468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
    Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
    J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.
    Parikh R; Patel L; Dalwadi S
    Drug Deliv; 2014 Sep; 21(6):406-11. PubMed ID: 24215141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Design of Spray-dried Porous Particles for Sugar-based Dry Powder Inhaler Formulation].
    Kadota K
    Yakugaku Zasshi; 2018; 138(9):1163-1167. PubMed ID: 30175760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.